1228930-61-7

Basic information

• Product Name: 2-(4-(2-chlorobenzyloxy)phenyl)ethanol
• Synonyms: 2-(4-(2-chlorobenzyloxy)phenyl)ethanol
• CAS NO: 1228930-61-7
• Molecular Weight: 262.736
• Mol File: 1228930-61-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(4-(2-chlorobenzyloxy)phenyl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(2-chlorobenzyloxy)phenyl)ethanol(1228930-61-7)
• EPA Substance Registry System: 2-(4-(2-chlorobenzyloxy)phenyl)ethanol(1228930-61-7)

Safety Data

• Hazardous Substances Data: 1228930-61-7(Hazardous Substances Data)

Upstream product

• 501-94-0 p-hydroxyphenethyl alcohol 
• 611-19-8 1-chloro-2-(chloromethyl)benzene 

Downstream Products

• 1334931-21-3 ethyl 2-(4-chlorobenzamido)-5-(4-(2-chlorobenzyloxy)phenyl)thiophene-3-carboxylate 
• 1334931-61-1 2-(4-chlorobenzamido)-5-(4-(2-chlorobenzyloxy)phenyl)thiophene-3-carboxylic acid 
• 202825-69-2 2-(4-(2-chlorobenzyloxy)phenyl)acetaldehyde 
• 1334930-95-8 ethyl 2-amino-5-(4-(2-chlorobenzyloxy)phenyl)thiophene-3-carboxylate 
• 1228930-92-4 C₁₅H₁₄ClIO 
• 1228930-93-5 C₂₅H₂₉ClN₂O₅ 
• 1228930-94-6 C₂₃H₂₇ClN₂O₄ 
• 1228930-51-5 C₁₉H₁₉ClN₂O₄ 
• 1228930-91-3 C₁₆H₁₇ClO₄S 

Relevant articles and documents

Novel immunomodulators based on an oxazolin-2-one-4-carboxamide scaffold

A series of oxazolidin-2-one-4-carboxylic amide compounds (1a-f) were designed and synthesized as the non-phosphate S1P1 receptor agonists. The single crystal of 1e was prepared and solved to elucidate the structure of 1a-f. EC50 of 1a-d were about 1.1-3.6 μM in S1P1 Redistribution assay, and their cytotoxicity was 8-40-fold lower than FTY720. Though its S1P1 agonist activities in vitro were about 1000-folds weaker than (S)-FTY720-P, at a dose of 10 mg/Kg, the immunosuppressive effects of 1a were comparable to FTY720. So oxazolidin-2-one-4-carboxylic amide derivatives were found as potential immunomodulator, compound 1a could be considered as a lead compound, rational modifications of 1a are anticipated using medicinal chemistry techniques and molecular modeling to obtain analogs with higher affinity and better clinical therapeutic properties.